Miami Children's Health Foundation (MCH Foundation) celebrated its 10th Anniversary Diamond Ball on Oct. 29, raising nearly $1.6 million, benefiting the children and families at Nicklaus Children’s Hospital. More than 800 guests took part in the glamourous affair, which combined couture fashion and costumes inspired by the theme “Into the Woods.”
This year, world-renowned guitarist, singer, and composer José Feliciano was inducted into the Ambassador David M. Walters International Pediatric Hall of Fame. After receiving his award, Mr. Feliciano also entertained the crowd with a live performance. Mr. Feliciano was recognized for his commitment to helping children through the Jose M. and Susan L. Feliciano Charitable Foundation for Children and the Arts and for his achievements in the world of music as the first Latin artist to cross over into the English music market.
To view the multimedia release go to:
http://www.multivu.com/players/English/7969051-miami-childrens-health-foundation-diamond-ball/
FAIR Health has launched a groundbreaking website, YouCanPlanForThis.org, aimed at transforming how people in New York State engage in healthcare planning. A next-generation transparency tool, the free site gives New Yorkers unprecedented access to accurate medical and dental costs and comprehensive educational resources, so they can plan financially for a procedure or episode of care. A national, independent, nonprofit organization dedicated to bringing transparency to healthcare costs and health insurance information, FAIR Health developed YouCanPlanForThis.org by building on its existing, award-winning consumer website and mobile app, with the support of the New York State Health Foundation (NYSHealth).
To view the multimedia release go to:
https://www.multivu.com/players/English/8087151-fair-health-youcanplanforthis-healthcare-planning/
Results from two national surveys of patients receiving chemotherapy and pharmacists, conducted by the Hematology/Oncology Pharmacy Association (HOPA) in collaboration with Eisai Inc.,* found that 83% of patients receiving chemotherapy who have experienced chemotherapy-induced nausea and vomiting (CINV) believe it is a side effect with which they must live. Results also showed that 95% of cancer patients surveyed believe that CINV has, at some point, had an impact on their daily lives. These national surveys are part of the Time to Talk CINV™ campaign, which aims to increase awareness among patients and caregivers about CINV prevention and the importance of speaking with their pharmacist and full healthcare team about this often preventable side effect.
“The survey results underscore the confusion patients who are undergoing chemotherapy have about CINV and the need for them to understand that there are ways to manage their symptoms so that they do not have to needlessly suffer with CINV,” said Scott Soefje, PharmD, MBA, BCOP, President, Hematology/Oncology Pharmacy Association (HOPA) and Director of Pharmacy at the University Medical Center Brackenridge in Austin, TX. “It is imperative that patients discuss CINV prevention early in treatment and with all members of the health care team, including pharmacists.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7560331-time-to-talk-cinv/
Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7496851-novo-nordisk-children-with-diabetes/
PDI, a leader in infection prevention products and solutions, announced the launch of its new EASY SCREEN™ CLEANING WIPE. This new product addresses the increasing use of touchscreen equipment in healthcare and the need for compatible cleaning products.
According to the Epocrates 2014 Mobile Trends Report, the presence of “digital omnivores,” a clinician regularly using digital devices including tablets, smartphones and computers, was 41 percent in 2014 and was predicted to increase to 74 percent in 2015. One of the biggest surges was expected to come from tablet usage, going from 45 percent in 2014 to 80 percent in 2015. Withstanding the apparent increase in touchscreen device usage in healthcare, a June 2015 study in the American Journal of Infection Control stated that proper protocols are lacking to address sensitive surfaces like touchscreen devices.
“Healthcare facilities are advancing everyday and it’s vital that we, as infection prevention leaders, are aware of the changes that are happening and able to adapt quickly. We created the EASY SCREEN™ CLEANING WIPE in response to the increasing usage of touchscreens and the need for a compatible product that wouldn’t damage the technology,” said PDI Senior Product Manager, Melanie Waddell.
To view the multimedia release go to:
http://www.multivu.com/players/English/7782451-pdi-easy-screen-cleaning-wipe/
Leveraging 130 years of knowledge and expertise across the Johnson & Johnson Family of Companies, Johnson & Johnson Medical Devices (JJMD) is proud to launch a new approach to help drive value-based healthcare in hospitals across Europe, Middle East and Africa (EMEA) – CareAdvantage. This is a data-driven, holistic approach in which JJMD partners with hospitals and other healthcare providers to provide a range of benefits, tailored to the customer’s specific needs and priorities.
The healthcare marketplace is changing, with intensifying pressure to meet the ‘triple aim’ of improving outcomes, increasing patient satisfaction and reducing costs. As the focus shifts from volume to value, there is a growing need for new delivery models, resulting in rapid transformation for hospital systems, clinicians and their patients.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8119051-johnson-medical-devices-careadvantage/
Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, commemorated its 50-year anniversary by awarding $150,000 in total grants to three organizations that share its goal to improve healthcare: The American Red Cross, the National Ovarian Cancer Coalition and Autism Speaks.
At a ceremony at the company’s flagship clinical laboratory in Teterboro, NJ, the company’s chairman, president and CEO Steve Rusckowski presented Health In Your Hands grants of $50,000 to representatives from each organization. Paul Brown, M.D., founder and former CEO of Quest’s predecessor company Metropolitan Pathology Laboratory, Inc. or MetPath, established in April, 1967, was also recognized at the event.
To view the multimedia release go to:
https://www.multivu.com/players/English/8080751-quest-diagnostics-50th-anniversary/
A Harvard School of Dental Medicine symposium recently featured data from United Concordia Dental’s landmark study as compelling evidence on the costly impact of poor oral health on overall wellness.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7052551-united-concordia-dental-research-featured-at-harvard-university-symposium/
Every 23 seconds, someone in the United States is diagnosed with diabetes. It's estimated that one in 11 Americans has the disease—more than 29 million people—and another 86 million have prediabetes and are at risk for developing type 2 diabetes. The numbers alone are staggering, and the people affected by the disease include those who have diabetes and their friends, family, caregivers and communities.
American Diabetes Month®, observed by the American Diabetes Association® (Association) every November, is a time to focus the nation's attention on the many people who are affected by diabetes and to raise the urgency about the need to address diabetes. To help spark a national conversation, the Association is asking people to share their stories about what it truly means to live with diabetes with a new campaign, This Is Diabetes™.
http://www.multivu.com/players/English/7711431-american-diabetes-month-thisisdiabetes/
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
The European Head and Neck Society (EHNS) and the Make Sense Campaign, today announced the launch of the Third Annual Head and Neck Cancer Awareness week (21–25 September). Through the pan-European Awareness Week, the EHNS and Make Sense Campaign promote education on head and neck cancer risk factors, disease prevention and disease signs and symptoms for both patients and healthcare professionals.
“Each year 350,000 people are diagnosed with head and neck cancer across Europe, and over half will not be alive after five years. However, if diagnosed and treated earlier, patients can have an 80 – 90% survival rate.” said Professor René Leemans, President of the EHNS and Professor and Chief of Otolaryngology – Head and Neck Surgery at VU University Medical Centre. “Through the Make Sense Campaign we are educating people about the early signs of the disease and encouraging them to seek professional help in a timely manner. Additionally, we are advocating for the best possible standards of patient care so that their outcomes can be optimised once they have been diagnosed with the disease.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7628151-support-head-neck-cancer-patients/
Global specialty plastics provider Eastman demonstrates the dominant performance of next-generation material Eastman MXF221 copolyester as a disinfectant-ready polymer for safer healthcare environments at the Medical Design & Manufacturing (MD&M) West trade show in Anaheim, California, Feb. 6 to 8. The latest advancement in biocompatible medical-grade polymers for medical device housings and hardware, Eastman MXF221 offers unsurpassed chemical compatibility with stringent disinfectants used to combat healthcare-associated infections (HAIs) as well as improved durability and impact strength.
To view the multimedia release go to:
https://www.multivu.com/players/English/8261151-eastman-disinfectant-ready-polymer-mdm-west/
Medical, health, technology, healthcare, treatment, Richard Fechter, interview, trade show, MultiVu 8261151